Synonym
Eptastigmine; BRN4883778; BRN-4883778; BRN 4883778
IUPAC/Chemical Name
Carbamic acid, heptyl-, 1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethylpyrrolo(2,3-b)indol-5-yl ester, (3aS-cis)-
InChi Key
RRGMXBQMCUKRLH-FPOVZHCZSA-N
InChi Code
InChI=1S/C21H33N3O2/c1-5-6-7-8-9-13-22-20(25)26-16-10-11-18-17(15-16)21(2)12-14-23(3)19(21)24(18)4/h10-11,15,19H,5-9,12-14H2,1-4H3,(H,22,25)/t19-,21-/m0/s1
SMILES Code
O=C(OC1=CC2=C(N(C)[C@@]3([H])[C@@]2(C)CCN3C)C=C1)NCCCCCCC
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
359.51
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Braida D, Sala M. Eptastigmine: ten years of pharmacology, toxicology, pharmacokinetic, and clinical studies. CNS Drug Rev. 2001 Winter;7(4):369-86. doi: 10.1111/j.1527-3458.2001.tb00205.x. PMID: 11830755; PMCID: PMC6741646.
2: Sahoo AK, Dandapat J, Dash UC, Kanhar S. Features and outcomes of drugs for combination therapy as multi-targets strategy to combat Alzheimer's disease. J Ethnopharmacol. 2018 Apr 6;215:42-73. doi: 10.1016/j.jep.2017.12.015. Epub 2017 Dec 14. PMID: 29248451.
3: Imbimbo BP, Martelli P, Troetel WM, Lucchelli F, Lucca U, Thal LJ. Efficacy and safety of eptastigmine for the treatment of patients with Alzheimer's disease. Neurology. 1999 Mar 10;52(4):700-8. doi: 10.1212/wnl.52.4.700. PMID: 10078713.
4: Cella SG, Imbimbo BP, Pieretti F, Müller EE. Eptastigmine augments basal and GHRH-stimulated growth hormone release in young and old dogs. Life Sci. 1993;53(5):389-95. doi: 10.1016/0024-3205(93)90642-g. PMID: 8336517.
5: Mant T, Troetel WM, Imbimbo BP. Maximum tolerated dose and pharmacodynamics of eptastigmine in elderly healthy volunteers. J Clin Pharmacol. 1998 Jul;38(7):610-7. doi: 10.1002/j.1552-4604.1998.tb04467.x. PMID: 9702845.
6: Imbimbo BP, Troetel WM, Martelli P, Lucchelli F. A 6-month, double-blind, placebo-controlled trial of eptastigmine in Alzheimer's disease. Dement Geriatr Cogn Disord. 2000 Jan-Feb;11(1):17-24. doi: 10.1159/000017208. PMID: 10629357.
7: Auteri A, Mosca A, Lattuada N, Luzzana M, Zecca L, Radice D, Imbimbo BP. Pharmacodynamics and pharmacokinetics of eptastigmine in elderly subjects. Eur J Clin Pharmacol. 1993;45(4):373-6. doi: 10.1007/BF00265958. PMID: 8299673.
8: Tammenmaa-Aho I, Asher R, Soares-Weiser K, Bergman H. Cholinergic medication for antipsychotic-induced tardive dyskinesia. Cochrane Database Syst Rev. 2018 Mar 19;3(3):CD000207. doi: 10.1002/14651858.CD000207.pub2. PMID: 29553158; PMCID: PMC6494194.
9: Braida D, Ottonello F, Sala M. Eptastigmine improves eight-arm radial maze performance in aged rats. Pharmacol Res. 2000 Oct;42(4):299-304. doi: 10.1006/phrs.2000.0706. PMID: 10987987.
10: Tuovinen K, Kaliste-Korhonen E, Raushel FM, Hänninen O. Eptastigmine- phosphotriesterase combination in DFP intoxication. Toxicol Appl Pharmacol. 1996 Oct;140(2):364-9. doi: 10.1006/taap.1996.0232. PMID: 8887453.
